

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	1	03/086386	WO	A1	2003-10-23	Novogen REsearch Pty., Ltd.		
	2	01/17986	WO	A1	2001-03-15	Novogen Research Pty., Ltd.		
	3	98/08503	WO	A1	1998-03-05	Kelly, G.		
	1	00/03707	WO	A1	2000-01-27	Laboratoire L. Lafon		Corresponds to CN1312712
	4	1312712	CN	A	2001-09-12	Laboratoire L. Lafon		Corresponds to WO0003707

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1	Abstract XP002541865, "Phenoxodiol enters phase II leukemia trial", DailyDrugNews.com (Daily Essentials), September 26, 2002	Abstract only
	2	ANDREAS I. CONSTANTINOU, et al., "Phenoxodiol (2H-1-Benzopyran-7-0,1,3-(4-hydroxyphenyl)), A Novel Isoflavone Derivative, Inhibits DNA Topoisomerase II by Stabilizing the Cleavable Complex", Anticancer Research, Vol. 22, No. 5, pp. 2581-2586, September 2002	
	3	TITO FOJO, et al., "Taxol and other microtubule-interactive agents", Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs, Vol. 2, No. 3, pp. 293-304, January 1, 2000	
	4	DIRK TH. SLEIJFER, et al., "Cisplatin: a review of clinical applications and renal toxicity", Pharmaceutish Weekblad Scientific Edition, Vol. 7, No. 6, pp. 237-244, December 13, 1985	
	5	ANTONA J. WAGSTAFF, et al., "Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer", Drugs, Vol. 37, No. 2, pp. 162-190, February 1989	
	6	Supplemental European Search Report dated September 4, 2009, issued in European Application No. 03798829.2	

EXAMINER SIGNATURE

Examiner Signature	/Benjamin Packard/	Date Considered	01/21/2010
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./